%0 Journal Article
%T 沙库巴曲缬沙坦在治疗射血分数保留的心衰中的有效性和安全性<br>Efficacy and Safety of Sacubitril-Valsartan in the Treatment of Heart Failure with Preserved Ejection Fraction
%A 陆燕莉
%A 邱福宇
%J Advances in Clinical Medicine
%P 1353-1359
%@ 2161-8720
%D 2020
%I Hans Publishing
%R 10.12677/ACM.2020.107204
%X <div style=\"text-align:justify;\">
	心力衰竭是绝大多数心血管疾病的终末阶段，病死率极高，射血分数保留的心衰(Heart Failure with preserved ejection fraction, HFpEF)已经成为心力衰竭的主要表现形式。在呼吸困难的患者中，HFpEF的诊断具有很大的挑战性，而且目前针对HFpEF的治疗缺少足够的循证医学证据。沙库巴曲缬沙坦是首个血管紧张素受体–脑啡肽酶双重抑制剂，是一种具有全新作用机制的治疗心衰的药物，已被指南推荐用于射血分数降低的心衰(HFrEF)患者。目前，该药物对HFpEF患者没有明确的适应症。然而，其复杂的作用机制以及先前的实验和临床数据似乎表明其在HFpEF中的潜在治疗作用。现将沙库巴曲缬沙坦在治疗射血分数保留的心衰中的有效性和安全性作一综述。<br />
Heart failure is the terminal stage of most cardiovascular diseases, with a very high mortality rate. Heart failure with preserved ejection fraction (HFpEF) has become the main manifestation of heart failure. In patients with dyspnea, the diagnosis of HFpEF is very challenging, and the current treatment targeting HFpEF lacks sufficient evidence-based medicine. Sacubitri-valsartan is the first dual inhibition of angiotensin receptor and neprilysin with a new mechanism of action for heart failure. It has been recommended by the guidelines for heart failure patients with reduced ejection fraction. At present, the drug has no clear indications for HFpEF patients. However, its complex mechanism of action and previous experimental and clinical data seem to indicate its potential therapeutic role in HFpEF. In this review, we summarize the efficacy and safety of sacubitril-valsartan in the treatment of HFpEF.
</div>
%K 射血分数保留的心衰，血管紧张素受体–脑啡肽酶抑制剂，沙库巴曲缬沙坦<br>Heart Failure with Preserved Ejection Fraction
%K Angiotensin Receptor-Neprilysin Inhibitor
%K Sacubitril-Valsartan
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=36601